Grid of patient photos with a blue background


The Virta Treatment reverses type 2 diabetes and other chronic metabolic diseases, safely and sustainably, without the risks, costs, or side effects of medications or surgery. Our mission is to reverse type 2 diabetes in 100 million people by 2025.

For press inquiries and interview requests, feel free to contact us at any time at

Virta Brand Assets

Download our press kit for the latest logos, product screenshots and company photos.

As Featured In

Forbes logoFortuneThe New York Times logoNewsweek logoTechCrunch logoLogo: Business Insider
“Virta gives diabetics a cross between a pocket doctor and a guardian angel.”

Newsweek, How Artificial Intelligence Will Cure America's Sick Health Care System

“Over the past two years, the Pequot Nation reduced its total medication spending by half, roughly $3,800 per [Virta] patient”

USA Today, Native American tribes have long struggled with high rates of diabetes, and COVID-19 made the problem even more urgent

“Virta’s virtual clinic can fill a gap between visits, which is important for people who are dealing with their diseases every day and need additional support.”

STAT, 5 burning questions about digital health and chronic disease management

“It's a much more scalable model than seeing people in a doctor's office.”

The New York Times, Tackling Weight Loss and Diabetes With Video Chats

“…Virta Health, is taking a more daring approach, which it hopes will ultimately eliminate the type 2 diabetes altogether.”

CNBC, This woman tattooed the logo of diabetes management start-up Virta Health on her arm to remind her to stick with the program

About Virta




Raised through Series E


States where Virta is available

Diabetes Trends (US)


People living with type 2 diabetes


People living with prediabetes


Economic burden of diabetes

Virta's Clinical Trial


Diabetes reversal rate* at 1 year¹


Patients who reduced or eliminated insulin at 1 year¹


Estimated savings per patient for the first two years²

Citations and Footnotes

  1. Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9. Reversal rate refers to % of patients with HbA1c less than 6.5% who are taking no diabetes-specific medications.
  2. Note: does not include consideration of Virta fees. Source: Virta internal analysis - Economic Impact Model built using Virta clinical results and published estimates of medical & pharmacy costs by A1c level and BMI from Li et. al., The Economic Burden of Obesity by Glycemic Stage in the United States; PharmacoEconomics (2015) 33:735–748.